PFAM Search:   
       by Pfam accession/ID, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  

Full view: branches of nodes matching the query are shown completely (Compact view)

(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Clan: Cyclin (63)
(-)
Family: CDK5_activator (2)
(-)
Homo sapiens (Human) (2)
1UNHE:147-294; E:147-294STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, ALOISINE AND INDIRUBIN.
3O0GE:145-293; E:145-293CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
(-)
Family: Cyclin (2)
(-)
Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Bakers yeast) (2)
2PK9D:33-170; D:33-170STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
2PMID:33-170; D:33-170STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
(-)
Family: Cyclin_C (40)
(-)
Bos taurus (Bovine) (2)
1VINA:309-427BOVINE CYCLIN A3
3MY5D:309-427; D:309-427CDK2/CYCLINA IN COMPLEX WITH DRB
(-)
Homo sapiens (Human) (36)
1JSTD:309-427; D:309-427PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
1JSUB:309-427P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1OGUD:309-427; D:309-427STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1OI9D:309-427; D:309-427STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIUD:309-427; D:309-427STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIYD:309-427; D:309-427STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OKVD:309-427; D:309-427CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
1OKWD:309-427; D:309-427CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
1OL1D:309-427; D:309-427CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
1P5ED:309-427; D:309-427THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS)
1PKDD:309-427; D:309-427THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
1QMZD:309-427; D:309-427PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1URCD:309-427; D:309-427CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
1VYWD:309-427; D:309-427STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2UUED:309-427; D:309-427REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2UZBD:309-427; D:309-427CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZDD:309-427; D:309-427CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZED:309-427; D:309-427CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZLD:309-427; D:309-427CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2V22D:309-427; D:309-427REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2WEVD:309-427; D:309-427TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WFYD:309-427; D:309-427TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WHBD:309-427; D:309-427TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WIHD:309-427; D:309-427STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2WIPD:309-427; D:309-427STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID
2WMAD:309-427; D:309-427STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2WMBD:309-427; D:309-427STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2WPAD:309-427; D:309-427OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2WXVD:309-427; D:309-427STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2X1ND:309-427; D:309-427TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2JGZB:300-418CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2W96A:155-265CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2W99A:155-267CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2W9FA:155-261CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2W9ZA:155-267CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1W98B:229-351THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
(-)
Mus musculus (Mouse) (2)
3QHRD:309-427; D:309-427STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
3QHWD:309-427; D:309-427STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
(-)
Family: Cyclin_N (51)
(-)
Bos taurus (Bovine) (2)
1VINA:181-307BOVINE CYCLIN A3
3MY5D:181-307; D:181-307CDK2/CYCLINA IN COMPLEX WITH DRB
(-)
Equus caballus (Horse) (1)
2W2HB:10-149; B:10-149STRUCTURAL BASIS OF TRANSCRIPTION ACTIVATION BY THE CYCLIN T1-TAT-TAR RNA COMPLEX FROM EIAV
(-)
Homo sapiens (Human) (43)
1JSTD:181-307; D:181-307PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
1JSUB:181-307P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1OGUD:181-307; D:181-307STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1OI9D:181-307; D:181-307STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIUD:181-307; D:181-307STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIYD:181-307; D:181-307STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OKVD:181-307; D:181-307CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
1OKWD:181-307; D:181-307CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
1OL1D:181-307; D:181-307CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
1P5ED:181-307; D:181-307THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS)
1PKDD:181-307; D:181-307THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
1QMZD:181-307; D:181-307PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1URCD:181-307; D:181-307CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
1VYWD:181-307; D:181-307STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2UUED:181-307; D:181-307REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2UZBD:181-307; D:181-307CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZDD:181-307; D:181-307CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZED:181-307; D:181-307CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZLD:181-307; D:181-307CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2V22D:181-307; D:181-307REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2WEVD:181-307; D:181-307TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WFYD:181-307; D:181-307TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WHBD:181-307; D:181-307TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WIHD:181-307; D:181-307STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2WIPD:181-307; D:181-307STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID
2WMAD:181-307; D:181-307STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2WMBD:181-307; D:181-307STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2WPAD:181-307; D:181-307OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2WXVD:181-307; D:181-307STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2X1ND:181-307; D:181-307TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2JGZB:173-298CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2W96A:26-153CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2W99A:26-153CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2W9FA:26-153CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2W9ZA:26-153CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1W98B:100-227THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
1JKWA:42-159STRUCTURE OF CYCLIN MCS2
1KXUA:42-159CYCLIN H, A POSITIVE REGULATORY SUBUNIT OF CDK ACTIVATING KINASE
2PK2D:9-149; D:9-149; D:9-149; D:9-149CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
3LQ5B:9-149STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
3MI9B:9-149CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
3MIAB:9-149CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
3MY1B:9-149STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
(-)
Mus musculus (Mouse) (2)
3QHRD:181-307; D:181-307STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
3QHWD:181-307; D:181-307STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
(-)
Saimiriine herpesvirus 2 (strain 11) (SaHV-2) (Herpesvirus saimiri) (2)
1JOWA:22-148CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1XO2A:22-148CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR, FISETIN
(-)
Schizosaccharomyces pombe (strain ATCC 38366 / 972) (Fission yeast) (1)
1ZP2A:12-133STRUCTURE OF THE MEDIATOR SUBUNIT CYCLIN C
(-)
Family: RB_A (4)
(-)
Homo sapiens (Human) (4)
1N4MB:380-573; B:380-573STRUCTURE OF RB TUMOR SUPPRESSOR BOUND TO THE TRANSACTIVATION DOMAIN OF E2F-2
1O9KG:379-573; G:379-573; G:379-573; G:379-573CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
2R7GC:380-573; C:380-573STRUCTURE OF THE RETINOBLASTOMA PROTEIN POCKET DOMAIN IN COMPLEX WITH ADENOVIRUS E1A CR1 DOMAIN
3POMB:382-573; B:382-573CRYSTAL STRUCTURE OF THE UNLIGANDED RETINOBLASTOMA PROTEIN POCKET DOMAIN
(-)
Family: RB_B (4)
(-)
Homo sapiens (Human) (4)
1N4MB:645-766; B:645-766STRUCTURE OF RB TUMOR SUPPRESSOR BOUND TO THE TRANSACTIVATION DOMAIN OF E2F-2
1O9KH:645-766; H:645-766; H:645-766; H:645-766CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
2R7GC:645-766; C:645-766STRUCTURE OF THE RETINOBLASTOMA PROTEIN POCKET DOMAIN IN COMPLEX WITH ADENOVIRUS E1A CR1 DOMAIN
3POMB:645-766; B:645-766CRYSTAL STRUCTURE OF THE UNLIGANDED RETINOBLASTOMA PROTEIN POCKET DOMAIN
(-)
Family: TFIIB (4)
(-)
Homo sapiens (Human) (3)
1TFBA:215-285; A:215-285NMR STUDIES OF HUMAN GENERAL TRANSCRIPTION FACTOR TFIIB: DYNAMICS AND INTERACTION WITH VP16 ACTIVATION DOMAIN, 20 STRUCTURES
1VOLA:215-285; A:215-285TFIIB (HUMAN CORE DOMAIN)/TBP (A.THALIANA)/TATA ELEMENT TERNARY COMPLEX
2PHGA:215-285; A:215-285MODEL FOR VP16 BINDING TO TFIIB
(-)
Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Bakers yeast) (1)
3K7AM:133-203CRYSTAL STRUCTURE OF AN RNA POLYMERASE II-TFIIB COMPLEX